Amryt Pharma Share Discussion Threads

[greendragon777] 04/1/2019 18:14

The reporting always confuses me but it appears there were 2 large buys reported late from this afternoon to the tune of about a million shares at nearly 18p. Hopefully this is the start of some institutional buying building a large position......before a takeover bid! 😉😃

[alphabravo321] 04/1/2019 17:36

Yes they definitely mentioned it towards the end, obviously the focus of today was 101 and 103 to a lesser extent but like you I would really like to see another good licensing deal

[waterloo01] 04/1/2019 17:27

Thanks, yes that's what I meant. Adding there will be the biggest boost to the SP, over and above positive AP101 trial). Adding income while developing makes it a much lower risk biotech.

[bazworth] 04/1/2019 17:26

mdalos1, you’re never stuck. You always have the option of selling. If you see better opportunities elsewhere, then sell AMRYT and buy the better opportuniy. It’s never wrong to take a loss, or indeed bank a profit!

[alphabravo321] 04/1/2019 17:15

They mentioned very briefly that they are actively looking for other licensing opportunities

[greendragon777] 04/1/2019 16:50

You mean another licencing type deal similar to Lojuxta Waterloo? No is the quick answer. It was just about AP101 and AP103 today but the management seemed pretty upbeat about both!

[waterloo01] 04/1/2019 16:44

Thanks. Any noises about the next drug alongside Lox?

[greendragon777] 04/1/2019 16:37

Nothing major to report from the conference call but Joe Wiley certainly seemed particularly excited about AP103 which he said there will be an update on very soon by the sound of it.

Rory Neelon answered the question with regard to the additional cost of the trial saying it would be something like €4-€5m but that was for the full trail period, it would obviously be a lot less to get to top line data point hence why Diamondstar's figure is probably about right as the medium term cash requirement.

Disappointing obviously that we didn't get a clean run on the trial which would most likely have triggered the warrants too but at least it wasn't futile so we can take comfort in that.

The gene therapy would clearly be a game changer if that was successful so it will be fantastic to bring that to the next stage.

I'm still bullish for now! 😃

[papillon] 04/1/2019 16:31

alphabravo321
Posts: 27
Opinion: No Opinion
Price: 17.05
What next? Today 16:01 It is interesting that although todays news although good is not the best we could have hopes for, that being said Anryt are much close to an approved EB treatment than Scioderm were when they were bought out by Amicus...will someone be willing to roll the dice and make an offer?

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

I presume that's what Cathal Friel is hoping for, alphabravo! :-). His decision to derisk and offload around 8m shares in May 2018 looks, at this moment in time, to have been a wise decision with the benefit of hindsight.


As you say, alphabravo, at least AP101 has jumped the Phase III interim analysis hurdle, unlike Amicus's Socioderm treatment. We may have clipped the hurdle, but the jockey is still in the saddle and AP101 is still aiming for the finishing post, albeit at a canter rather than a gallop, but as AP101 is the only horse left standing in the race what does a few extra months matter as long as it crosses the finishing line? Only one more hurdle to jump! Still all to play for!

PS. I continue to hold all my circa 40k of shares for the time being. Let's see what next week brings!

[bazworth] 04/1/2019 15:36

I'm holding v tight and 'clenching my cheeks' having recently lost slightly more than a bucketload of FTC of late. The F Type is looking pretty much dead in the water!!

[diamondstar1] 04/1/2019 15:32

Interesting if you read the Amryt RNS release on 26 Sep 2018, they actually predicted top line results for EASE in H2 2019. Today, they are still projecting EASE top line in H2 2019. Hence, the need for additional 48 patients has likely pushed study back by about 4 months, in my estimation. They will open new sites eg in USA, to compensate for the need for more patients. This will also incur more costs:- I estimate, around £2 million extra.

On the plus side, I am really looking forward to the AP103 preclinical results. Gene therapies are clearly highly specific - I expect these studies conducted in in vivo (live animal) models to be positive. Hopefully, those who were inpatient and sold off today, will be regretting their decision.

[papillon] 04/1/2019 15:23

My predicted share price range was always 7p - 35p DEPENDENT on the EASE trial news, bazworth. Check back through my posts! I always give my share price range and never a specific target share price because I haven't got a crystal ball.

Today's news could have been better, but look on the bright side, bazworth, it could have been a lot worse! :-). If I sold my circa 40k now at least I'd have made a profit; not much though!

[bazworth] 04/1/2019 15:12

You folk giving your share price predictions seem to be a little way away from actual......!

[papillon] 04/1/2019 15:07

I was tempted to sell half of my AMYT shares after today's news, alphabravo (around 20k), but I'll wait and see what the AP103 update says before coming to any decision.

[alphabravo321] 04/1/2019 15:03

Wiley just said on CC that AP 103 news is "imminent"

[papillon] 04/1/2019 15:00

"Amryt will begin the recruitment process for the additional patients required and now expects a readout of the top line data from the EASE study in H2 2019."

We originally expected the EASE top line data readout in H2 2018, greendragon! What's another year? :-) Yet more patience required!! Par for the course, I suppose, if we insist on gambling on AIM listed biopharmas and natural resource stocks :-).

Let's hope we get some good news on AP103 in the short term (hopefully next week!):

"Amryt expects to report results from pre-clinical studies of AP103 shortly."

[greendragon777] 04/1/2019 14:31

I'm on hold waiting for the conference call. Hopefully it'll give us some more details.

Agreed Paps, hopefully we'll see a bit of institutional interest from next week.

[papillon] 04/1/2019 14:13

Not bad news today, but not fantastically great news either?? I can't see the 24p warrants being exercised next week, unless there is a significant rise in the AMYT share price before next Friday. Why exercise the warrants when it's currently far cheaper to buy in the Mkt?

If the 24p warrants are not exercised then that's circa £5m of useful cash that AMYT will have lost. The 5m Euro tranche of the EIB loan that AMYT can now draw down following today's news will come in handy, but the circa £5m warrant money would be a disappointing loss of cash for AMYT.

Today's news doesn't seem to have sparked much investor interest. The analyst call at 2:30pm could have a beneficial effect on the share price next week. Let's hope for some institutional buying interest next week.

[bazworth] 04/1/2019 13:38

Trust me to be out cycling when news broke!!

[greendragon777] 04/1/2019 13:34

Has anyone got a link to the conference call today?

[bermudashorts] 04/1/2019 13:33

Great news.

[greendragon777] 04/1/2019 13:32

The wait is over and at least it's the best we could hope for on the second option. We are now substantially de-risked compared to before the announcement so it's defo a positive.

Perhaps Diamondstar could share his thought on today's news? What is a 'modest' increase in numbers do you think?

Overall I'm pretty happy with that and I wouldn't be surprised if we start to see a considerable increase in interest in AMYT over the coming months.

I agree Paps, we will probably see a steady increase after today's news as it may take more time to digest and get some potentially larger investors interested. Maybe now would be the time AMYT could get an Amicus type option offer like they did before.

Interesting times ahead folks and well done for holding through the tough times! 😃